The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Mesenchymal Stem Cell Targeting of Microscopic Tumors and Tumor Stroma Development Monitored by Noninvasive In vivo Positron Emission Tomography Imaging
Open accessAbstract
The aim of this study was to assess the efficacy human mesenchymal stem cells (hMSC) for targeting microscopic tumors and suicide gene or cytokine gene therapy. Immunodeficient mice were transplanted s.c. with human colon cancer cells of HT-29 Inv2 or CCS line, and 3 to 4 days later, i.v. with “tracer” hMSCs expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) and enhanced green fluorescent protein (EGFP) reporter genes. Subsequently, these tumors were examined for specificity and magnitude of HSV1-TK+, EGFP+ stem cell engraftment and proliferation in tumor stroma by in vivo positron emission tomography (PET) with 18F-labeled 9-(4-fluoro-3-hydroxymethylbutyl)-guanine ([18F]-FHBG). In vivo PET images of tumors growing for 4 weeks showed the presence of HSV1-TK+ tumor stroma with an average of 0.36 ± 0.24% ID/g [18F]-FHBG accumulation. In vivo imaging results were validated by in situ correlative histochemical, immunofluorescent, and cytometric analyses, which revealed EGFP expression in vWF+ and CD31+ endothelial cells of capillaries and larger blood vessels, in germinal layer of dermis and hair follicles proximal to the s.c. tumor site. These differentiated HSV1-TK+, GFP+ endothelial cells had limited proliferative capacity and a short life span of <2 weeks in tumor fragments transplanted into secondary hosts. We conclude that hMSCs can target microscopic tumors, subsequently proliferate and differentiate, and contribute to formation of a significant portion of tumor stroma. PET imaging should facilitate clinical translation of stem cell–based anticancer gene therapeutic approaches by providing the means for in vivo noninvasive whole-body monitoring of trafficking, tumor targeting, and proliferation of HSV1-tk-expressing “tracer” hMSCs in tumor stroma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSC can be mobilized and recruited to active tumor sites, where they can incorporate into the tumor’s microenvironment [5, 68, 100–103].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Bone marrow cells regenerate infarcted myocardium
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J. M., McKay, R. D. G., Nadal‐Ginard, B., Bodine, D. M., et al. (2001) · Nature · doi:10.1038/35070587 · Cited by 5,149
Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues
Prockop, D. J. (1997) · Science · doi:10.1126/science.276.5309.71 · Cited by 4,629
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,222
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V. E., Traverso, G., Romans, K. E., Montgomery, E. A., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,859
Aboody, K. S., Brown, A. B., Rainov, N. G., Bower, K. A., Liu, S., Yang, W., Small, J. E., Herrlinger, U., Ourednik, V., Black, P. M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12846 · Cited by 1,207
Self-citationOrigin of endothelial progenitors in human postnatal bone marrow
Reyes, M., Dudek, A. Z., Jahagirdar, B., Koodie, L., Marker, P. H., & Verfaillie, C. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14327 · Cited by 1,105
(2002) · PubMed · Cited by 903
Cited by
Sorted by citations
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Fass, L. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.04.001 · Cited by 855
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
“These data were confirmed in other tumor models [31,32], most recently by Weinberg et al.”
ResultKidd, S. M., Spaeth, E. L., Dembinski, J. L., Dietrich, M. F., Watson, K., Klopp, A. H., Battula, V. L., Weil, M., Andreeff, M., & Marini, F. C. (2009) · Stem Cells · doi:10.1002/stem.187 · Cited by 680
Cancer associated fibroblasts: the dark side of the coin.
Cirri, P., & Chiarugi, P. (2011) · Europe PMC (PubMed Central) · Cited by 512
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431
“tumors originated from human colon cancer cells HT-29 (20).”
BackgroundBone marrow-derived mesenchymal stem cells and the tumor microenvironment
Bergfeld, S. A., & DeClerck, Y. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9222-7 · Cited by 345
“) injection in mice, utilizing fluorescence, bioluminescence, positron emission, and magnetic resonance-based reporter labeling [66-68].”
MethodCancer Stem Cells: The Promise and the Potential
Ajani, J. A., Song, S., Höchster, H. S., & Steinberg, I. B. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.01.001 · Cited by 318
“Hung and colleagues showed that MSCs are capable of migrating to sites of colon cancer propagation and are able to differentiate into endothelial cells required for tumor angiogenesis.(94) Recently, MSCs were shown to differentiate into tumor-associated fibroblasts through Notch and TGF-β signaling pathways via direct…”
BackgroundVascular endothelial growth factor can signal through platelet-derived growth factor receptors
Ball, S. G., Shuttleworth, C. A., & Kielty, C. M. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200608093 · Cited by 276
“(Hung et al., 2005), forming the basis for novel therapeutic ap-”
BackgroundFibroblasts as architects of cancer pathogenesis
Marsh, T., Pietras, K., & McAllister, S. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.10.013 · Cited by 277
“Bone marrow-derived MSCs have been of interest due to their ability to home to sites of inflammation, tissue repair, and neoplasia in experimental models [52-54].”
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 259
The role of the myofibroblast in tumor stroma remodeling
Otranto, M., Sarrazy, V., Bonté, F., Hinz, B., Gabbiani, G., & Desmoulière, A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20377 · Cited by 261
Mesenchymal stem cells enhance growth and metastasis of colon cancer
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Kodama, M., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25440 · Cited by 308
Concise Review: Mesenchymal Stem Cell Tumor-Homing: Detection Methods in Disease Model Systems
Reagan, M. R., & Kaplan, D. L. (2011) · Stem Cells · doi:10.1002/stem.645 · Cited by 230
Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers
Lecarpentier, Y., Schussler, O., Hébert, J., & Vallée, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01248 · Cited by 251
Mesenchymal stem cells promote growth and angiogenesis of tumors in mice
Huang, W.-H., Chang, M.-C., Tsai, K.-S., Hung, M., Chen, H.-L., & Hung, S.-C. (2012) · Oncogene · doi:10.1038/onc.2012.458 · Cited by 233
Self-citationCho, J. A., Park, H., Lim, E. H., Kim, K. H., Choi, J. S., Lee, J. H., Shin, J. W., & Lee, K. W. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.005 · Cited by 225
“A growing body of evidence suggests that MSCs are potential precursors for tumor stroma, and can serve as targeted delivery vehicles for anti-cancer agents [16,17].”
BackgroundLoebinger, M. R., Kyrtatos, P. G., Turmaine, M., Price, A. N., Pankhurst, Q. A., Lythgoe, M. F., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1912 · Cited by 212
“The noninvasive tracking of MSCs has previously been studied with the use of bioluminescence (22) and whole-body micropositron emission tomography (23) with MSCs labeled with firefly luciferase or transduced to express HSV1-TK, respectively.”
MethodXu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
“[15] demonstrated that MSCs could target microscopic tumours, subsequently proliferate and differentiate and then contribute to formation of a significant portion of tumor stroma in human colon cancer.”
BackgroundRen, C., Kumar, S., Chanda, D., Kallman, L., Chen, J., Mountz, J. D., & Ponnazhagan, S. (2008) · Gene Therapy · doi:10.1038/gt.2008.101 · Cited by 204
Tumor cell behaviour modulation by mesenchymal stromal cells
Kučerová, L., Matúšková, M., Hlubinova, K., Altanerová, V., & Altaner, Č. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-129 · Cited by 204
“have shown MSC incorporation into established subcutaneous HT-29 xenotransplants accompanied by loss of mesenchymal concomitant with endothelial marker expression [38].”
BackgroundPositron emission tomography: An overview
Shukla, A., & Kumar, U. (2006) · Journal of Medical Physics · doi:10.4103/0971-6203.25665 · Cited by 192
“Stem cell research The transplantation of stem cells with damaged tissue had offered tremendous potential for therapeutic applications in a wide range of disease conditions.([19,20]) including myocardial infarction and Parkinson’s disease.”
BackgroundCavarretta, I. T. R., Altanerová, V., Matúšková, M., Kučerová, L., Čulig, Z., & Altaner, Č. (2009) · Molecular Therapy · doi:10.1038/mt.2009.237 · Cited by 189
Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players
Barcellos‐de‐Souza, P., Gori, V., Bambi, F., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.10.004 · Cited by 187
“Many reports describe that BM-MSC can home and engraft to different types of solid tumors, includingbreast [12–15], lung [16,17], pancreatic [18], colon [19,20], ovarian [21–23] and prostate carcinomas [24,25], melanoma [26], glioma [27,28], Kaposi's sarcoma [29], and osteosarcoma [30] among other primary andmetastati…”
BackgroundMesenchymal stroma: Role in osteosarcoma progression
Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171
Mesenchymal stem cells and neovascularization: role of platelet‐derived growth factor receptors
Ball, S. G., Shuttleworth, C. A., & Kielty, C. M. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00120.x · Cited by 183
“MSCs systemically administered into a murine tumour model, were shown to localize and engraft into tumour lesions, where they proliferated, differentiated into vWF- and CD31-positive endothelial-like cells and formed a significant fraction of the tumour stroma [121].”
BackgroundMesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice
Tsai, K., Yang, S., Lei, Y., Tsai, C., Chen, H., Hsu, C., Chen, L., Wang, H., Miller, S. A., Chiou, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.045 · Cited by 178
Self-citationHSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells
Matúšková, M., Hlubinova, K., Pastorakova, A., Hunáková, Ľ., Altanerová, V., Altaner, Č., & Kučerová, L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.028 · Cited by 171
“Furthermore, FACS sorted immortalized mesenchymal stem cells expressing HSVTK1 exhibited in vitro susceptibility to ganciclovir with LD50 = 10 lM GCV [25].”
BackgroundImmunological properties of mesenchymal stem cells and clinical implications
Patel, S. A., Sherman, L. S., Munoz, J. L., & Rameshwar, P. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0001-x · Cited by 172
“In a study that assessed the invasion of MSCs into metastatic tumors, MSCs facilitated the formation of tumor stroma [ 20 ].”
BackgroundMesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
Liposome imaging agents in personalized medicine
Petersen, A. L., Hansen, A. E., Gabizon, A., & Andresen, T. L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.003 · Cited by 164
Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope
Chhabra, P., & Brayman, K. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0116 · Cited by 157
Yang, N., Ding, Y., Zhang, Y., Wang, B., Zhao, X., Cheng, K., Huang, Y., Taleb, M., Zhao, J. T., Dong, W., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05363 · Cited by 164
Gao, P., Ding, Q., Wu, Z., Jiang, H., & Fang, Z. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.031 · Cited by 161
Meier, R. P. H., Müller, Y. D., Morel, P., Gonelle‐Gispert, C., & Bühler, L. H. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.08.011 · Cited by 156
Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo
Li, L., Tian, H., Yue, W., Zhu, F., Li, S., & Li, W. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22511 · Cited by 149
“…stromal fibroblasts (Studeny et al., 2004; Spaeth et al., 2009), promoting tumor vessel formation (Galmiche et al., 1993; Al-Khaldi et al., 2003; Hung et al., 2005; Zhu et al., 2006; Liu et al., 2007; Sun et al., 2008), constructing cancer stem cell niches and inducing immunosuppressive effect…”
BackgroundMultipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies
Casiraghi, F., Remuzzi, G., Abbate, M., & Perico, N. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9345-4 · Cited by 150
“Human immortalized MSC injected in the tail vein of mice with preestablished colon cancer cells localized in capillary-like structures and within the inner layer of small arterioles and in connective tissue of the tumor, and enhanced tumor growth [60].”
Pancreatic cancer stromal biology and therapy
Xie, D., & Xie, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.01.002 · Cited by 139
“Similar concepts are confirmed in other tumor models.(60,69,70) Also, Karnoub et al reported that tumor cells recruit MSCs to tumor xenografts(54) and are addicted to the chemokine CCL5 secreted from MSCs for their metastatic spread.”
ResultAltaner, Č. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.023 · Cited by 138
“Moreover exogenously administered MSCs could form a significant proportion of tumor mass [75,78].”
BackgroundCombined PET/MRI: one step further in multimodality imaging
Sauter, A. W., Wehrl, H. F., Kolb, A., Judenhofer, M. S., & Pichler, B. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.08.003 · Cited by 133
Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells
Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007) · STEM CELLS · doi:10.1634/stemcells.2006-0461 · Cited by 164
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V., & Altaner, C. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1239 · Cited by 171
“The amount of the systemically administered therapeutic cells to home within the tumour was estimated to less then 10% of the tumour mass [8,9].”
BackgroundRoorda, B. D., ter Elst, A., Kamps, W. A., & de Bont, E. S. J. M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.06.004 · Cited by 131
“urthermore, systemically injected MSCs were shown to ocalize and engraft into tumors, where they proliferated, ifferentiated into vWF- and CD31-positive endothelial-like ells and formed a significant fraction of the tumor micronvironment [69].”
BackgroundGaliè, M., Konstantinidou, G., Peroni, D., Scambi, I., Marchini, C., Lisi, V., Krampera, M., Magnani, P., Merigo, F., Montani, M., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210920 · Cited by 130
“Their contribution to generating tumor stroma (Hung et al., 2005; Wolf et al., 2005), especially its reactive subpopulations (Direkze et al., 2004), has already been suggested; so they could be candidates for the tumorpromoting or tumorigenic phenotypical changes that a neoplastic microenvironment…”
BackgroundDevelopment of a Tumor-Selective Approach to Treat Metastatic Cancer
Aboody, K. S., Bush, R. A., Garcia, E. P., Metz, M. Z., Najbauer, J., Justus, K. A., Phelps, D. A., Remack, J. S., Yoon, K. J., Gillespie, S., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000023 · Cited by 125
“Two concerns that must be addressed before the type of approach described in that study can be incorporated into clinical trials are, first, that MSCs continue to replicate in vivo and also incorporate into tumor stroma, constituting a significant fraction of the stromal tissue and possibly supporting tumor growth [43…”
BackgroundDeciphering the role of stroma in pancreatic cancer
Waghray, M., Yalamanchili, M., di Magliano, M. P., & Simeone, D. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328363affe · Cited by 128
“Mesenchymal stem cells (MSCs) have attracted great interest because their presence has recently been identified in human tumors and they have been shown to have the ability to migrate and engraft to areas of tumor development [18].”
BackgroundCostea, D. E., Tsinkalovsky, O., Vintermyr, O., Johannessen, A., & Mackenzie, I. C. (2006) · Oral Diseases · doi:10.1111/j.1601-0825.2006.01264.x · Cited by 123
The therapeutic potential of mesenchymal stem cells
Picinich, S. C., Mishra, P. J., Mishra, P. J., Glod, J. W., & Banerjee, D. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.965 · Cited by 125
“Microscopic tumors Preclinical MSCs migrate to tumors and form tumor stroma [41]”
BackgroundGu, E., Chen, W.-Y., Gu, J., Burridge, P. W., & Wu, J. C. (2012) · Theranostics · doi:10.7150/thno.3666 · Cited by 123
“18F-FHBG has been used to assess tracking and survival of MSCs in porcine myocardium [62] as well as to assess migration of MSCs to tumor stroma [63].”
MethodSelf-citationHypoxia-Induced Secretion of TGF-β1 in Mesenchymal Stem Cell Promotes Breast Cancer Cell Progression
Hung, S.-P., Yang, M.-H., Tseng, K.-F., & Lee, O. K. (2013) · Cell Transplantation · doi:10.3727/096368912x657954 · Cited by 137
Self-citationRecent advances in regenerative medicine strategies for cancer treatment
Mansouri, V., Beheshtizadeh, N., Gharibshahian, M., Sabouri, L., Varzandeh, M., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111875 · Cited by 115
Imaging of Mesenchymal Stem Cell Transplant by Bioluminescence and PET
Love, Z., Wang, F., Dennis, J. E., Awadallah, A., Salem, N., Lin, Y., Weisenberger, A. G., Majewski, S., Gerson, S. L., & Lee, Z. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043166 · Cited by 107
“In particular, the differences between this study and another MSC tracking study (19) were as follows: this study was a general-purpose investigation of an imaging-based MSC tracking technique, whereas the other study focused on tumor metastasis tracking; primary hMSCs were used in this study instead of immortalized M…”
BackgroundResultZhang, Y. S., Wang, Y., Wang, L., Wang, Y., Cai, X., Zhang, C., Wang, L. V., & Younan Xia, A. (2013) · Theranostics · doi:10.7150/thno.5369 · Cited by 104
“Nuclear imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), provide deep, three-dimensional (3D) imaging with high sensitivity [12-14].”
BackgroundTumor-educated mesenchymal stem cells promote pro-metastatic phenotype
Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A. (2017) · Oncotarget · doi:10.18632/oncotarget.20265 · Cited by 111
Toward Brain Tumor Gene Therapy Using Multipotent Mesenchymal Stromal Cell Vectors
Bexell, D., Scheding, S., & Bengzon, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.58 · Cited by 101
Metabolic and molecular imaging in neuro-oncology
Herholz, K., Coope, D. J., & Jackson, A. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70192-8 · Cited by 100
Involvement of endothelial progenitor cells in tumor vascularization
Patenaude, A., Parker, J., & Karsan, A. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.01.007 · Cited by 103
Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors
Martínez‐Quintanilla, J., Bhere, D., Heidari, P., He, D., Mahmood, U., & Shah, K. (2013) · Stem Cells · doi:10.1002/stem.1355 · Cited by 101
Ponomarev, V., Doubrovin, M., Shavrin, A., Serganova, I. S., Beresten, T., Ageyeva, L., Cai, C., Balatoni, J., Alauddin, M. M., & Gelovani, J. G. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.036962 · Cited by 98
Self-citationRamamonjisoa, N., & Ackerstaff, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00003 · Cited by 93
Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Hong, H., Yang, Y., Zhang, Y., & Cai, W. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791384234 · Cited by 95
“microscopic tumors and suicide gene or cytokine gene therapy, immunodeficient mice were transplanted with human cancer cells and subsequently injected with a small number of MSCs expressing both the HSV1-tk and enhanced GFP (EGFP) reporter genes [71].”
BackgroundLong term non-invasive imaging of embryonic stem cells using reporter genes
Sun, N., Lee, A. S., & Wu, J. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.100 · Cited by 94
“and 1,000 cells per mm 3 for small animal PET imagin”
Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway
Hsu, H., Lin, J.-H., Hsu, T.-W., Su, K., Wang, C.-W., Yang, K., Chiou, S., & Hung, S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.001 · Cited by 93
Self-citationWei, H.-J., Zeng, R., Lu, J.-H., Lai, W. T., Chen, W.-H., Liu, H., Chang, Y.-T., & Deng, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3481 · Cited by 92
“After homing, the administered MSCs could differentiate into vascular endothelial and stromal cells to form the vessels and stroma of tumors [5].”
Self-citationGenetic modification of stem cells for transplantation
Phillips, M. I., & Tang, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.035 · Cited by 96
“Hung et al used micropositron emission tomography imaging with [18F]-FHBG to monitor the pTYEFEGFP-TK vector modified human MSCs. Micropositron emission tomography imaging revealed that tracer human MSCs could migrate to the sites of microscopic tumor lesions, engraft into these microscopic tumor lesions, and contribu…”
BackgroundGao, Y., Yao, A., Zhang, W., Lu, S., Yu, Y., Deng, L., Yin, A., Xia, Y., Sun, B., & Wang, X. (2010) · Oncogene · doi:10.1038/onc.2010.38 · Cited by 91
“administered hMSCs have also been demonstrated in some subcutaneous tumor models (Studeny et al., 2002; Hung et al., 2005).”
BackgroundFOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells
Wei, H.-J., Nickoloff, J. A., Chen, W.-H., Liu, H., Lo, W., Chang, Y.-T., Yang, P., Wu, C., Williams, D. F., Gelovani, J. G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2413 · Cited by 87
“We previously demonstrated that MSCs can migrate to and engraft into microscopic tumor lesions [14].”
BackgroundSelf-citationHonoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90
Signaling pathways in the regulation of cancer stem cells and associated targeted therapy
Wang, M., & Wu, M. (2022) · MedComm · doi:10.1002/mco2.176 · Cited by 96
Mesenchymal Stem Cells in Cancer
Stagg, J. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9030-4 · Cited by 95
Knoop, K., Kolokythas, M., Klutz, K., Willhauck, M. J., Wunderlich, N., Draganovici, D., Zach, C., Gildehaus, F., Böning, G., Göke, B., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.93 · Cited by 88
Mesenchymal stem cells: A new platform for targeting suicide genes in cancer
Tehrani, R. M., Verdi, J., Noureddini, M., Salehi, R., Salarinia, R., Mosallaei, M., Simonian, M., Alani, B., Ghiasi, M. R., Jaafari, M. R., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26094 · Cited by 85
“In order to achieve efficient homing of MSCs to the tumor site, the median amount of administered therapeutic cells recommended to be less than 10% of the tumor mass (Hung et al., 2005).”
BackgroundDwyer, R. M., Ryan, J., Havelin, R. J., Morris, J. C., Miller, B. W., Liu, Z., Flavin, R., O’Flatharta, C., Foley, M. J., Barrett, H. H., et al. (2011) · Stem Cells · doi:10.1002/stem.665 · Cited by 89
Magatti, M., Munari, S. D., Vertua, E., & Parolini, O. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01531.x · Cited by 84
“[18–20], suggesting that MSCs might be an attractive tool for developing novel cancer treatments.”
BackgroundBian, Z., Fan, Q., Li, G., Xu, W., & Tang, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01731.x · Cited by 83
Shojaei, S., Hashemi, S. M., Ghanbarian, H., Salehi, M., & Mohammadi‐Yeganeh, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27326 · Cited by 89
“MSCs tumor homing have been observed in some cancers, such as breast, ovarian, lung, and colon carcinomas (Goldstein, Reagan, Anderson, Kaplan, & Rosenblatt, 2010; Hung et al., 2005; Komarova, Roth, Alvarez, Curiel, & Pereboeva, 2010).”
Lin, J., Wang, J., Chen, M., Chen, H.-C., Chang, T.-H., Su, B.-W., & Chang, P. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.06.003 · Cited by 80
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Onoyama, M., Ohnishi, M., Ohara, E., Higashi, Y., Tanaka, S., Yasui, W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27735 · Cited by 80
Chen, X., Wang, R., Zhao, X., Wei, Y., Hu, M., Wang, Y.-S., Zhang, X.-W., Zhang, R., Zhang, L., Yao, B., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl069 · Cited by 81
The role of mesenchymal stem cells in cancer development
Yagi, H., & Kitagawa, Y. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00261 · Cited by 76
“The homing capacity toward cancer tissues has been evaluated mostly in MSCs derived from bone marrow (Hung et al., 2005; Nakamizo et al., 2005; Loebinger et al., 2009) and less from other tissues such as adipocytes (Grisendi et al., 2010) or umbilical cord blood (Hu et al., 2011).”
BackgroundExpanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Barca, C., Griessinger, C. M., Faust, A., Depke, D. A., Essler, M., Windhorst, A. D., Devoogdt, N., Brindle, K. M., Schäfers, M. A., Zinnhardt, B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph15010013 · Cited by 73
“There have been many trials of mesenchymal stem cells (MSCs) as cell-based drug delivery systems in which tumors homing and assessment of their therapeutic effects were monitored by transducing the cells with HSV-1-tk to allow their visualization using PET [97,103].”
MethodLuetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., & Schmoll, H. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00794.x · Cited by 72
“However, tumour integration [7, 38, 39] and even proliferation [8] of systemically applied MSC was seen in s.”
BackgroundAquino, J. B., Bolontrade, M. F., García, M. G., Podhajcer, O. L., & Mazzolini, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.10 · Cited by 71
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas
Kerrigan, B. C. P., Shimizu, Y., Andreeff, M., & Lang, F. F. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.02.002 · Cited by 72
“Soon thereafter, the use of MSCs for the treatment of various other types of cancers was reported, including in the treatment of, lung [33], colon [8], ovarian [34], pancreatic [35], renal [11], breast cancers [36] and sarcoma [9, 10].”
BackgroundLotfi, R., Eisenbacher, J. L., Solgi, G., Fuchs, K., Yildiz, T., Nienhaus, C., Rojewski, M., & Schrezenmeier, H. (2011) · European Journal of Immunology · doi:10.1002/eji.201041324 · Cited by 66
García, M. G., Bayo, J., Bolontrade, M. F., Sganga, L., Malvicini, M., Alaniz, L. D., Aquino, J. B., Fiore, E. J., Rizzo, M., Rodriguez, A., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200137c · Cited by 66
Nouri, F. S., Wang, X., & Hatefi, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.003 · Cited by 62
“Recent evidence indicates that systemically administered mesencymal stem cells (MSCs) can migrate and deliver therapeutic genes to tumors [1-3].”
BackgroundQiao, L., Zhao, T., Wang, F.-Z., Shan, C., Ye, L., & Zhang, X. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00751.x · Cited by 63
The Effect of Delivery Via Narrow-Bore Needles on Mesenchymal Cells
Agashi, K., Chau, D. Y. S., & Shakesheff, K. M. (2008) · Regenerative Medicine · doi:10.2217/17460751.4.1.49 · Cited by 64
To grab the stroma by the horns: From biology to cancer therapy with mesenchymal stem cells
Droujinine, I. A., Eckert, M. A., & Zhao, W. (2013) · Oncotarget · doi:10.18632/oncotarget.1040 · Cited by 64
“The evidence for this has been obtained using MSC-specific PCR, immunohistochemistry (IHC) (29–31) and noninvasive, real-time bioluminescence imaging (16,32,33), nuclear magnetic resonance imaging (MRI) (34), positron emission tomography (PET) (35), and radionuclide imaging (35).”
MethodTargeting of mesenchymal stem cells to ovarian tumors via an artificial receptor
Komarova, S., Roth, J. C., Alvarez, R. D., Curiel, D. T., & Pereboeva, L. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-12 · Cited by 62
“a means to track malignant tissues or for the delivery of anticancer agents to tumors [2,5-9].”
BackgroundPerin, E. C., Tian, M., Marini, F. C., Silva, G. V., Zheng, Y. W., Baimbridge, F., Quan, X., Fernandes, M. R., Gahremanpour, A., Young, D. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022949 · Cited by 61
“We [18,19] and others [20] have shown the efficacy of PET imaging of HSV1-tk reporter gene– expressing stem cells in preclinical studies [18–20], including studies of short-term stem cell fate after intramyocardial injection in rodent models of MI [21–23], mesenchymal stem cells (MSCs) implanted in pig hearts [24,25],…”
BackgroundSelf-citationTakigawa, H., Kitadai, Y., Shinagawa, K., Yuge, R., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2016) · Cancer Science · doi:10.1111/cas.12907 · Cited by 62
Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors
Amara, I., Touati, W., Beaune, P. H., & de Waziers, I. (2014) · Biochimie · doi:10.1016/j.biochi.2014.06.016 · Cited by 64
Kim, K. S., Park, W., & Na, K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.014 · Cited by 59
Choi, S. H., Stuckey, D. W., Pignatta, S., Reinshagen, C., Khalsa, J. K., Roozendaal, N., Martínez‐Quintanilla, J., Tamura, K., Keleş, E., & Shah, K. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0077 · Cited by 59
“PET ligands such as 18F-FHBG, 18F-FEAU, and 124I-FAIU have been used to provide 3D images of the concentration of cells in different locations within a tumor (49, 50).”
MethodFruhwirth, G. O., Diocou, S., Blower, P. J., Ng, T., & Mullen, G. E. D. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.127480 · Cited by 58
“Recently, several groups successfully introduced NIS as a reporter gene to enable imaging or therapy (with 131 I 2 ) in nonthyroidal disease ( 17 ) including the use of mesenchymal stem cells for tumor targeting ( 18,19 ).”
BackgroundStem Cell Imaging: Tools to Improve Cell Delivery and Viability
Wang, J., & Jokerst, J. V. (2016) · Stem Cells International · doi:10.1155/2016/9240652 · Cited by 57
“Reporter genes such as those transfected by HSV-1tk cannot be easily recognized, and thus a GFP gene is usually added on the same construct as the reporter to guide in FACS sorting [21].”
Metadata
- Authors
- Hung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., Wei, H.-J., & Gelovani, J. G.
- Affiliations
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Taipei Medical University (TW)
- Taipei Veterans General Hospital (TW)
- 2Institute of Biomedical Materials, Taipei Medical University; Departments of
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Clinical Cancer Research
- Published
- 2005-11-01
- Volume
- 11
- Issue
- 21
- Pages
- 7749-7756
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149287721
- Cited by
- 268
- References
- 46
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 10 · 2017: 12 · 2016: 19 · 2015: 17 · 2014: 15 · 2013: 29 · 2012: 19
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, Los Angeles
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- mesenchymal stem cells, tumor targeting, tumor stroma, HSV-1 thymidine kinase, suicide gene therapy, cytokine gene therapy, 18F-FHBG, stem cell differentiation, endothelial cells, colon cancer, HT-29 cells, non-invasive imaging, stem cell trafficking
- MeSH terms
- Animals, Cell Membrane, Flow Cytometry, Genetic Vectors, Humans, Immunohistochemistry, Mesoderm, Neoplasm Transplantation, Neoplasms, Stem Cells, Time Factors, Protein Biosynthesis, Genetic Therapy, Lentivirus, Polymerase Chain Reaction, Cytokines, Genes, Reporter, Platelet Endothelial Cell Adhesion Molecule-1, Cell Line, Tumor, Cell Proliferation, Positron-Emission Tomography, Green Fluorescent Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
